2022 Ljubljana, Slovenia

I-01 João Abrantes
ADaMO: End-to-end automation of Pharmacometric modelling in drug development, from dataset building to output generation
Wednesday 09:45-11:15
I-02 Nicolas Azzopardi
Mechanistic model of contrast-enhanced ultrasound in colorectal cancer metastasis.
Wednesday 09:45-11:15
I-03 Freya Bachmann
Computing Optimal Drug Dosing with OptiDose: Implementation in NONMEM
Wednesday 09:45-11:15
I-04 Aliénor Bergès
Model informed drug development to accelerate clinical development in life cycle innovation
Wednesday 09:45-11:15
I-05 Monir Bertayli
Dose determination of morphine to investigate the analgesic effects of morphine and pregabalin in healthy subjects using a combined NONMEM model
Wednesday 09:45-11:15
I-06 Mattia Berton
Repository of model parameters for physiologically based pharmacokinetic modelling in obese validated against triazolam and caffeine observed data
Wednesday 09:45-11:15
I-07 Jantine Brussee
Population PK modelling for the iminosugar lucerastat supports dose adaptation in patients with Fabry disease and moderate to severe renal impairment
Wednesday 09:45-11:15
I-08 Laura Bukkems
Relationship between factor VIII activity levels and bleeding for rFVIII-SingleChain in patients with severe hemophilia A
Wednesday 09:45-11:15
I-09 Myriam Chartoire
Investigation of the design of the capsaicin cough challenge test
Wednesday 09:45-11:15
I-10 Chao Chen
The area under the effect curve as a preclinical-to-clinical translation tool for predicting therapeutic dose of anti-infectives
Wednesday 09:45-11:15
I-11 Henrik Cordes
Species-specific Expression Databases for Physiologically Based Pharmacokinetic Modeling
Wednesday 09:45-11:15
I-12 Vincent Croixmarie
Dose selection and adaptation strategy in renal impaired patients for a phase 2 study with a Clinical Trial Simulation strategy
Wednesday 09:45-11:15
I-13 Anna Dari
Quantifying the Persistence of Immunogenicity After a Single Dose of Ad26.COV2.S in Humans Using a Mechanistic Modeling & Simulation Approach
Wednesday 09:45-11:15
I-14 Alessandro Di Deo
Evaluation of the pharmacokinetics of tideglusib in congenital and childhood myotonic dystrophy type 1 using Bayesian priors
Wednesday 09:45-11:15
I-15 Alan Faraj
Model-informed dose selection in phase-3 trials for prophylactic treatment with dalcinonacog alfa in adult and pediatric hemophilia B patients
Wednesday 09:45-11:15
I-16 Alan Faraj
A joint ketamine and esketamine exposure-response model of MADRS score in major depressive disorder to enable informed trial design for candidate drugs with similar mode of action
Wednesday 09:45-11:15
I-17 Thomas Frank
Population pharmacokinetic/pharmacodynamic modeling to demonstrate comparability of exposure and activity of insulin aspart Sanofi
Wednesday 09:45-11:15
I-18 Aline Fuchs
The human FcRn transgenic mice Tg32 as a model for early assessment and prediction of human pharmacokinetics of monoclonal antibodies
Wednesday 09:45-11:15
I-19 Iztok Grabnar
Pharmacokinetic-pharmacodynamic model of fentanyl sedation in children with severe acute bronchiolitis
Wednesday 09:45-11:15
I-20 Mélanie Guhl
Computation of standard errors at finite distance in non linear mixed effects models
Wednesday 09:45-11:15
I-21 Benjamin Guiastrennec
A Bounded Integer Approach to Evaluate AIMS Score for Austedo in Patients with Tardive Dyskinesia
Wednesday 09:45-11:15
I-22 Seiichi Hayato
Population pharmacokinetics and exposure-response analyses of amyloid PET SUVr and plasma biomarkers Aβ42/40 ratio and p-tau181 for lecanemab in subjects with early Alzheimer’s disease
Wednesday 09:45-11:15
I-23 Chih-hsuan Hsin
Hepatic impairment affects pharmacokinetics and pharmacodynamics of selatogrel, a novel subcutaneous P2Y12 receptor antagonist
Wednesday 09:45-11:15
I-24 Laura Iavarone
Application of the Area Under the Effect Curve as in vivo efficacy driver in Visceral Leishmaniasis
Wednesday 09:45-11:15
I-25 Woojin Jung
Containerized NONMEM and its assistant software in R development environment
Wednesday 09:45-11:15
I-26 Angela Khodzhayev
Esophageal Eosinophil Count and the Endoscopic Reference Score Remodeling Subscore Do Not Correlate in Placebo Treated Eosinophilic Esophagitis Patients: Phase 2 Proof-of-Concept and Phase 3 TREET Studies
Wednesday 09:45-11:15
I-27 Jane Knöchel
Accelerating clinical development of a novel PCSK9 antisense oligonucleotide using semi-mechanistic pharmacodynamic modelling
Wednesday 09:45-11:15
I-28 Silvia Maria Lavezzi
Translational pharmacology benchmarking of a novel drug candidate for an autoimmune disease
Wednesday 09:45-11:15
I-29 Olivier Le Tilly
Non-linear pharmacokinetics of eculizumab in atypical haemolytic uremic syndrome
Wednesday 09:45-11:15
I-30 Feiyan Liu
A system pharmacology Boolean network model for the TLR4-mediated host response in early sepsis
Wednesday 09:45-11:15
I-31 Igor Locatelli
A Bayesian mixed treatment comparison meta-analysis of pulmonary arterial hypertension therapies
Wednesday 09:45-11:15
I-32 Nicolas Luyckx
Campsis: A generic, easy-to-use and intuitive PK/PD simulation platform based on R packages RxODE and mrgsolve
Wednesday 09:45-11:15
I-33 Vincent Madelain
Multicompartmental PKPD model to inform active exposure of nucleic acid therapeutic candidate in CNS disease
Wednesday 09:45-11:15
I-34 Parsshava Mehta
Application of interspecies PBPK modeling to characterize BBB permeability and assess target site exposure-response using levetiracetam as model drug
Wednesday 09:45-11:15
I-35 Frano Mihaljevic
Development of a level A in vitro/in vivo correlation (IVIVC) using applications of the MonolixSuite
Wednesday 09:45-11:15
I-36 Anna Mishina
Simulation of Rituximab and Natalizumab biomarker efficacy using simplified QSP model of B- and T- lymphocyte dynamics in Multiple Sclerosis
Wednesday 09:45-11:15
I-37 Joo Young Na
Population pharmacokinetic analysis of omeprazole according to CYP2C19 polymorphism in elderly subjects
Wednesday 09:45-11:15
I-38 Chiara Nicolò
MS TreatSim: A clinical trial simulator for Relapsing-remitting Multiple Sclerosis
Wednesday 09:45-11:15
I-39 Marije Otto
Application of Item Response Theory in Early Phase Clinical Trials: Utilization of a Reference Model to Analyse the Montgomery-Åsberg Depression Rating Scale.
Wednesday 09:45-11:15
I-40 Theodoros Papathanasiou
PKPD Exploratory Graphics (xGx) Cheat Sheet
Wednesday 09:45-11:15
I-41 Tiffany Pela
Quality of Life and Symptom Burden Among Patients With Eosinophilic Esophagitis in a Real-World Setting
Wednesday 09:45-11:15
I-42 Carlos Perez-Ruixo
Population pharmacokinetic modelling of selexipag and its active metabolite after oral and intravenous administration in adult pulmonary arterial hypertension patients
Wednesday 09:45-11:15
I-43 Christoph Pfaffendorf
Population pharmacokinetic model of atovaquone in infants to adults
Wednesday 09:45-11:15
I-44 Thao Nguyen Pham
Combining aggregate data and individual patient/subject data in model-based meta-analysis: An illustrative case study of tofacitinib in rheumatoid arthritis patients
Wednesday 09:45-11:15
I-45 Elodie Plan
Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357 treatment
Wednesday 09:45-11:15
I-46 Anne Ravix
Population pharmacokinetic study of lacosamide in children and adults with epilepsy
Wednesday 09:45-11:15
I-47 Mar Ribera I Armengol
A perspective on the kinetics of the oral administration of Mirabegron to treat overactive bladder in spinal cord injury patients
Wednesday 09:45-11:15
I-48 Christelle Rodrigues
Using preclinical data to predict human pharmacokinetics of monoclonal antibodies for first-in-human dose setting: A review of five internal case studies
Wednesday 09:45-11:15
I-49 Karine Rodriguez-Fernandez
External validation of a population pharmacokinetic model of adalimumab in patients with hidradenitis suppurativa
Wednesday 09:45-11:15
I-50 Viktor Rognås
An integrated semi-mechanistic model to predict the outcome of drug-target effects on the erythropoietic system
Wednesday 09:45-11:15
I-51 Sergio Sánchez Herrero
Ground-breaking software for modelling, simulation, optimization, estimation and validation applications in drug development timeline processes.
Wednesday 09:45-11:15
I-52 Marina Savelieva
Pharmacometrics and Integrated Evidence Generation: example of ligelizumab in Chronic Spontaneous Urticaria
Wednesday 09:45-11:15
I-53 Daniel Seeler
Towards a qualitative systems biology model to study the effect of blood flow responsive CCM and NO signaling on endothelial cell morphology
Wednesday 09:45-11:15
I-54 Sejung Hwang
Population pharmacokinetic analysis to investigate the effect of ethnicity for extrapolating data from Caucasians to Koreans in eslicarbazepine acetate therapy
Wednesday 09:45-11:15
I-55 Alexander Solms
Reduced FXI levels do not appear to increase bleeding risk in End-Stage Kidney Disease patients - results from an exploratory PK/PD and ER analysis of FXI-ASO
Wednesday 09:45-11:15
I-56 Gilles Tiraboschi
Population Pharmacokinetic and Pharmacodynamic Analyses of Olipudase alfa in Adult and Pediatric Patients with the rare Acid Sphingomyelinase Deficiency (Niemann-Pick) lysosomal storage disease
Wednesday 09:45-11:15
I-57 Thi Quyen Tran
Population pharmacokinetics of a truncated milk fat globule-EGF factor 8 (NP-011) for optimal dose prediction on liver fibrosis
Wednesday 09:45-11:15
I-58 Pauline Traynard
Validation of non-compartmental analysis (NCA) and bioequivalence results of PKanalix with respect to Phoenix WinNonLin and SAS.
Wednesday 09:45-11:15
I-59 carla troisi
Population pharmacokinetics of continuous infusion ampicillin in the treatment of enterococcal infections in adult hospitalised patients
Wednesday 09:45-11:15
I-60 Monika Twarogowska
A library of parent-metabolite models for the MonolixSuite
Wednesday 09:45-11:15
I-61 Paul van den Berg
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis
Wednesday 09:45-11:15
I-62 Aartje Maria van der Kuijl
Identifiability of drug effects in turn-over models with increasing complexity
Wednesday 09:45-11:15
I-63 Xiaofeng Wang
Exposure–response modelling of aripiprazole and brexpiprazole in adults and adolescents with schizophrenia to support extrapolation of efficacy in adolescents
Wednesday 09:45-11:15
I-64 Zhigang Wang
Higher clearance of therapeutic antibodies is associated with worse endoscopic outcomes in patients with Crohn’s disease
Wednesday 09:45-11:15